Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Julien Adam

Showing results (71-80 of 152) with videos related to

Pageof 16
Sort By:
Cardiovascular and Interventional Radiology|May 8, 2019
Focus on Recommendations for the Management of Non-small Cell Lung CancerPernelle Lavaud, Benjamin Besse, Thierry de Baere, et al.
European Journal of Immunology|August 2, 2017
High proportion of PD-1-expressing CD4<sup>+</sup> T cells in adipose tissue constitutes an immunomodulatory microenvironment that may support HIV persistenceAbderaouf Damouche, Guillaume Pourcher, Valérie Pourcher, et al.
European Journal of Cancer (Oxford, England : 1990)|June 11, 2026
Cytokines released by human tumors are independent from cancer histotypeMaria Kuksin, Severine Mouraud, Delphine Bredel, et al.
Anti-Cancer Drugs|October 27, 2016
Trabectedin in advanced desmoplastic round cell tumors: a retrospective single-center seriesBenjamin Verret, Charles Honore, Sarah Dumont, et al.
Journal of Thoracic Disease|September 4, 2018
Endobronchial ultrasound-guided fine-needle aspiration for pulmonary carcinomas genotyping: experience with 398 cases including rapid <i>EGFR/KRAS</i> analysis in 43 casesMaria-Rosa Ghigna, Adrian Crutu, Valentina Florea, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 17, 2021
A PD-1/PD-L1 Proximity Assay as a Theranostic Marker for PD-1 Blockade in Patients with Metastatic MelanomaIsabelle Girault, Julien Adam, Shensi Shen, et al.
Cancers|November 13, 2021
CD8+ T Lymphocytes Immune Depletion and LAG-3 Overexpression in Hodgkin Lymphoma Tumor Microenvironment Exposed to Anti-PD-1 ImmunotherapyJean-Marie Michot, Severine Mouraud, Julien Adam, et al.
Oncotarget|March 27, 2016
Phase I trial evaluating the antiviral agent Cidofovir in combination with chemoradiation in cervical cancer patientsEric Deutsch, Christine Haie-Meder, Mohamed Amine Bayar, et al.
JAMA Oncology|June 30, 2017
Use of PD-1 Targeting, Macrophage Infiltration, and IDO Pathway Activation in Sarcomas: A Phase 2 Clinical TrialMaud Toulmonde, Nicolas Penel, Julien Adam, et al.
The Oncologist|January 11, 2019
Brain Metastases and Place of Antiangiogenic Therapies in Alveolar Soft Part Sarcoma: A Retrospective Analysis of the French Sarcoma GroupGabriel G Malouf, Guillaume Beinse, Julien Adam, et al.
Pageof 16

Showing results (71-80 of 152) with videos related to

Sort By:
Pageof 16
Cardiovascular and Interventional Radiology|May 8, 2019
Focus on Recommendations for the Management of Non-small Cell Lung CancerPernelle Lavaud, Benjamin Besse, Thierry de Baere, et al.
European Journal of Immunology|August 2, 2017
High proportion of PD-1-expressing CD4<sup>+</sup> T cells in adipose tissue constitutes an immunomodulatory microenvironment that may support HIV persistenceAbderaouf Damouche, Guillaume Pourcher, Valérie Pourcher, et al.
European Journal of Cancer (Oxford, England : 1990)|June 11, 2026
Cytokines released by human tumors are independent from cancer histotypeMaria Kuksin, Severine Mouraud, Delphine Bredel, et al.
Anti-Cancer Drugs|October 27, 2016
Trabectedin in advanced desmoplastic round cell tumors: a retrospective single-center seriesBenjamin Verret, Charles Honore, Sarah Dumont, et al.
Journal of Thoracic Disease|September 4, 2018
Endobronchial ultrasound-guided fine-needle aspiration for pulmonary carcinomas genotyping: experience with 398 cases including rapid <i>EGFR/KRAS</i> analysis in 43 casesMaria-Rosa Ghigna, Adrian Crutu, Valentina Florea, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 17, 2021
A PD-1/PD-L1 Proximity Assay as a Theranostic Marker for PD-1 Blockade in Patients with Metastatic MelanomaIsabelle Girault, Julien Adam, Shensi Shen, et al.
Cancers|November 13, 2021
CD8+ T Lymphocytes Immune Depletion and LAG-3 Overexpression in Hodgkin Lymphoma Tumor Microenvironment Exposed to Anti-PD-1 ImmunotherapyJean-Marie Michot, Severine Mouraud, Julien Adam, et al.
Oncotarget|March 27, 2016
Phase I trial evaluating the antiviral agent Cidofovir in combination with chemoradiation in cervical cancer patientsEric Deutsch, Christine Haie-Meder, Mohamed Amine Bayar, et al.
JAMA Oncology|June 30, 2017
Use of PD-1 Targeting, Macrophage Infiltration, and IDO Pathway Activation in Sarcomas: A Phase 2 Clinical TrialMaud Toulmonde, Nicolas Penel, Julien Adam, et al.
The Oncologist|January 11, 2019
Brain Metastases and Place of Antiangiogenic Therapies in Alveolar Soft Part Sarcoma: A Retrospective Analysis of the French Sarcoma GroupGabriel G Malouf, Guillaume Beinse, Julien Adam, et al.
Pageof 16